Disitamab vedotin utilizes MMAE to bind to HER2-expressing cancer cells, where the ADC undergoes endocytosis, at which time enzymatic digestion causes the release of toxins that cleave the linker to release MMAE [59]. The gene discussed is ERBB2; the disease is cancer.